Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.00
Bid: 1,701.00
Ask: 1,701.50
Change: 32.00 (1.91%)
Spread: 0.50 (0.029%)
Open: 1,685.50
High: 1,718.50
Low: 1,673.00
Prev. Close: 1,673.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Big Pharma's bet on Big Data creates opportunities and risks

Tue, 26th Jan 2016 13:07

* Novartis plans to sell cloud-connected inhaler by 2019

* Part of companies' push into "Medical Internet of Things"

* Pharma and tech firms teaming up in hunt for Big Data

* But web-enabled devices present privacy and security risks

By John Miller

ZURICH, Jan 26 (Reuters) - Novartis wants everypuff of its emphysema drug Onbrez to go into the cloud.

The Swiss drugmaker has teamed up with U.S. technology firmQualcomm to develop an internet-connected inhaler thatcan send information about how often it is used to remotecomputer servers known as the cloud.

This kind of new medical technology is designed to allowpatients to keep track of their drug usage on their smartphonesor tablets and for their doctors to instantly access the dataover the web to monitor their condition.

It also creates a host of "Big Data" opportunities for thecompanies involved - with huge amounts of information about amedical condition and the efficacy of a drug or device beingwirelessly transmitted to a database from potentially thousands,even millions, of patients.

The potential scale of the so-called "Medical Internet ofThings" has not been lost on pharmaceutical and tech firmsaround the world, both big companies hunting growth and smallerones looking to provide bespoke products and services.

It has created unlikely alliances.

Novartis' domestic rival Roche has also teamed upwith Qualcomm and Danish diabetes drugmaker Novo Nordisk has partnered with IBM on cloud-linked deviceprojects, for example, while healthcare device maker Medtronic is working with a U.S. data-analytics firm Glooko.

GlaxoSmithKline, meanwhile, is in talks withQualcomm about a medical technology joint venture potentiallyworth up to $1 billion, according to people familiar with thematter.

However, with the opportunity comes risk.

Security experts warn that hacked medical information can beworth more than credit card details on the black market asfraudsters can use it to fake IDs to buy medical equipment ordrugs that can be resold, or file bogus insurance claims.

The U.S. Centers for Disease Control and Preventionestimates there are 35 million U.S. hospital discharges a year,a billion doctor and hospital visits and even moreprescriptions, much of which is stored in cloud databases.

CLOUD CONCERN

Now the "Medical Internet of Things" is introducing more andmore web-connected devices into the equation and pushing evenmore confidential patient data on to the cloud.

This is creating potential new opportunities for thievesseeking to penetrate medical companies' security where they maytarget names, birth dates, policy numbers, billing data and thediagnosis codes needed to obtain drugs, say experts.

"The weakest link tends to be the medical device itself,"said Rick Valencia, senior vice president of Qualcomm Life,Qualcomm's four-year-old healthcare unit. "They weren't designedwith the idea in mind that they would be going over the networkand the information would be residing in cloud infrastructure."

Medtronic, the world's largest standalone medical devicemaker, said in 2014 it lost patient records in separatecyberattacks at its diabetes business.

"The more information, the easier identity theft is and themore valuable the profiles that the hacker can sell to thirdparties," said Erik Vollebregt, a lawyer in Amsterdam whospecialises in medical device cybersecurity and privacy.

He said it could also be possible for criminals to hack intoweb-connected medical devices, and threaten the lives ofpatients, to blackmail the manufacturer.

Despite no documented patient-endangering hacks, the U.S.Food and Drug Administration warned last year an infusion pumpcould be vulnerable to attack and asked healthcare providers tostop using it.

SMART LENS

Novartis aims to have its inhaler for chronic lung disease,to be on the market by 2019. Other pharma-tech alliances includeAerocrine and Microsoft, which are workingtogether on a cloud project to analyse data from allergy andasthma patients.

Google is, meanwhile, working with Frenchdrugmaker Sanofi to collect and analyse informationfrom diabetes sufferers. The U.S. tech giant alsohas a partnership with Novartis to develop a smart contact lensthat can monitor diabetics' glucose levels.

All the companies involved in such projects say they aregoing to extreme lengths to protect patients' data from hackers.

Philips has turned to San Francisco-basedidentity-management software maker ForgeRock to keep data fromthe Dutch company's medical devices from falling into the wronghands.

Software security expert Marie Moe, of Norway's SINTEFscientific research foundation, said the wireless ports in thepacemaker that keeps her heart beating left it vulnerable tointrusion - but that she could not survive without the device.

"Wireless interfaces are a great benefit to certain patientgroups," she told Reuters. "But as a security researcher, I knowconnectivity also means vulnerability." (Additional reporting by Julie Steenhuysen in Chicago, JimFinkle in Boston and Ben Hirschler in London; Editing by PravinChar)

More News
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.